140. Dorabe syndrome Clinical trials / Disease details
Clinical trials : 104 / Drugs : 61 - (DrugBank : 14) / Drug target genes : 48 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-101116 | 01/4/2010 | 28/04/2010 | Open Phase III Study of ME2080 in Patients with Dravet Syndrome | Open Phase III Study of ME2080 in Patients with Dravet Syndrome | Dravet Syndrome | Intervention name : ME2080 (stiripentol) Dosage And administration of the intervention : 50mg/kg/day administered twice or 3 times a day (maximum 2500mg/day) | Meiji Seika Pharma Co., Ltd. (formerly MEIJI SEIKA KAISHA Co., LTD.) | NULL | 1 | 30 | BOTH | 25 | Phase 3 | NULL |